Clinical and Laboratory Investigations
Failure of Intralesional Propranolol in Infantile Hemangiomas
Version of Record online: 3 SEP 2013
© 2013 Wiley Periodicals, Inc.
Volume 31, Issue 2, pages 156–158, March/April 2014
How to Cite
Torres-Pradilla, M. and Baselga, E. (2014), Failure of Intralesional Propranolol in Infantile Hemangiomas. Pediatric Dermatology, 31: 156–158. doi: 10.1111/pde.12175
- Issue online: 9 MAR 2014
- Version of Record online: 3 SEP 2013
The purpose of this study was to evaluate the use of intralesional propranolol injection in the management of small, noncomplicated infantile hemangiomas (IHs) located in areas of cosmetic concern. A prospective study was performed in six female infants with small, non-complicated IHs in areas of cosmetic concern. The parents had refused oral propranolol or the patients had no response to topical timolol or had relapsed after oral propranolol and the parents refused further systemic treatment. All six patients were treated with 1 mg/mL propranolol solution at a dose of 0.2 mL/cm2. The size, color, and growth of the hemangiomas were monitored and recorded every 4 weeks. Treatment response was evaluated using a 5-point scale: much better (+2), better (+1), same (0), worse (−1), and much worse (−2). Heart rate and blood pressure were measured before and 1 hour after each injection. Adverse effects after medication were evaluated and managed accordingly. All hemangiomas stopped growing during therapy, but no significant changes in size or color were observed, even after repeated injections, and all patients were evaluated as 0 (same). One patient whose hemangioma stopped growing during treatment presented rebound growth after therapy cessation. No changes in heart rate or blood pressure were observed after intralesional propranolol injection. Adverse effects observed were pain and redness after injection. Intralesional propranolol seems safe but is not effective for the treatment of IH.